Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Nifty moved in a tight range of 82 points, and ended slightly below the psychologically crucial level of 15,700. NEW DELHI: ...

The Nifty Pharma index closed on a positive note on Tuesday. Shares of Glenmark Pharmaceuticals Ltd.(up 3.55 per cent), Ipca ...

The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Amid the stock market frenzy surrounding weight-loss medicines, one Belgian biotech company is rewarding investors by ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

The Indian pharmaceutical sector is anticipating a mixed quarter with overall slow growth, but key players like Dr. Reddy's ...

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Sanofi is still plugging away with its oral ... development processes and data in a centralised platform. The Global Pharma and Biotech Summit is the essential annual event for you to stay on ...